This is a population-based analysis performed to evaluate the prognostic factors and survival of patients with sebaceous carcinoma of the eyelid. Patients with eyelid sebaceous carcinoma from 1973-2013 were identified from the Surveillance, Epidemiology and End Results (SEER) database and data regarding patient age, year of diagnosis, sex, race, laterality, treatment modality, tumour size, tumour extent, lymph node involvement, and tumour grade was extracted. The SEER database collects and publishes cancer incidence and survival outcome data from population-based cancer registries in the United States. The majority (84.6%) were treated with surgery, 1% with radiation only, 4.6% with both surgery and radiation, and 8% with neither surgery nor radiation. Precise tumour size was unknown in 68.4% and regional and distal metastasis were found in 13.2% and 1.9% respectively. Histologically, the tumour was graded as well, moderately or poorly differentiated, however, grade was unknown in 65.1%. There was an increasing trend per decade from 1973, however, it is not known whether this is due to increasing reporting. Overall survival derived from Kaplan-Meier analysis was 66% and 44% at five and 10 years respectively. There was no statistical significant difference with the grade of tumour and overall survival though histological grade of tumour was unknown in 65.1%. Survival varied with treatment modality. Patients who received surgical treatment only showed higher median overall survival (10.3 years) compared to radiation only (3.0 years) and combined surgery and radiation (6.1 years). Overall survival varied with tumour size; shorter survival for tumours more than 20mm in size. However, tumour size was unknown in more than half of patients. Similarly, patients with lymph node involvement had shorter overall survival than one without.

Impact of clinicopathologic factors on survival in patients with sebaceous carcinoma of the eyelid – a population-based analysis.
Lee IJ, Koh JY.
Share This
Rina Bhatt

Wolverhampton Eye Infirmary, UK.

View Full Profile